BackgroundNon-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved antitumor effi Abstract Background: Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved...

- Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy - - Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically...

This is a paid press release. Contact the press release distributor directly with any inquiries. HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer HUTCHMED (China) Limited Mon, September 28, 2026 at 8:00 PM...

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that...

Hutchmed Begins Phase Ia Clinical Trial of KRAS-EGFR Antibody Conjugate Cancer Therapy Published on 09/27/2026 at 11:59 pm EDT MT Newswires This article is reserved for our members.Log in to continueLog inCreate an account Continue with Google Continue with Apple...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830...

HUTCHMED (China) ( ($HK:0013) ) has provided an update. HUTCHMED has begun the Phase Ia portion of a global first-in-human trial of HMPL-A830, a first-in-class KRAS HUTCHMED (China) ( (HK:0013) ) has provided an update. HUTCHMED has begun the Phase...